Skip to main content

Pulnovo Medical

Pulnovo's PADN Cuts Clinical Worsening Risk 51% in NEJM-Published Trial

Shanghai – September 08, 2026 -- Pulnovo Medical's pulmonary artery denervation (PADN) system reduced the risk of clinical worsening by 51% in patients with pulmonary hypertension linked to left heart disease (PH-LHD), according to results from the PADN-HF-PH trial presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in The New England Journal of Medicine.

Trial enrolled 264 patients across multiple centers under academician Yaling Han

The multicenter, randomized controlled study, led by academician Yaling Han of the General Hospital of Northern Theater Command, evaluated PADN as an add-on to guideline-directed medical therapy (GDMT) versus GDMT alone. Corresponding authors on the NEJM paper include Professor Shao-Liang Chen of Nanjing First Hospital and Professor Gregg W. Stone of Mount Sinai Hospital.

Pulnovo's PADN Device Cuts Heart Failure Risk 51% in Trial

Shanghai – September 08, 2026 -- Pulnovo Medical's pulmonary artery denervation (PADN) system reduced the risk of clinical worsening by 51% in patients with pulmonary hypertension linked to left heart disease, according to results from the PADN-HF-PH trial presented at the European Society of Cardiology (ESC) 2026 Congress and published simultaneously in The New England Journal of Medicine (NEJM).

Trial of 264 patients shows 51% risk reduction over two-year follow-up

The multicenter, randomized controlled trial, led by academician Yaling Han of the General Hospital of Northern Theater Command, enrolled 264 patients with pulmonary hypertension associated with left heart disease (PH-LHD). Over a median follow-up of 338 days, the estimated two-year incidence of clinical worsening was 25.7% in the PADN-plus-GDMT group versus 51.5% in the guideline-directed medical therapy (GDMT)-alone group (hazard ratio 0.49; 95% CI, 0.30 to 0.82; p=0.006).